Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors

Neuro-Oncology

Volumn 14, Issue 10, 2012, Pages 1203-1214

  Armstrong, Terri S ^a,b   Wen, Patrick Y ^c   Gilbert, Mark R ^b   Schiff, David ^d  

^a UTHSC SON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

brain tumors; chemotherapy; toxicity

Indexed keywords

AMLODIPINE; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CALCIUM CHANNEL BLOCKING AGENT; CEDIRANIB; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERLOTINIB; FELODIPINE; IRINOTECAN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THALIDOMIDE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ANGINA PECTORIS; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOPTYSIS; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CANCER; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; OVARY CANCER; PERIPHERAL VASCULAR DISEASE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; TUMOR BLEEDING; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84863794415     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor223     Document Type: Conference Paper

References (86)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352: 987-996.
2. Prados MD, Gutin PH, Phillips TL, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys. 1992;23: 3-8.
3. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 2004;58: 1147-1152.
4. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366: 985-990.
5. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83: 588-593.
6. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oli-goastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17: 2762-2771.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285: 1182-1186.
8. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res. 2006;312: 594-607.
9. Sholley MM, Ferguson GP, Seibel HR, et al. Mechanisms of neovascu-larization. Vascular sprouting can occur without proliferation of endo-thelial cells. Lab Invest. 1984;51: 624-634.
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25: 581-611.
11. Bacher M, Schrader J, Thompson N, et al. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol. 2003;162: 11-17.
12. Dasari VR, Kaur K, Velpula KK, et al. Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblast-oma. Aging (Albany NY). 2010;2: 791-803.
13. Wong ET, Brem S. Taming glioblastoma by targeting angiogenesis: 3 years later. J Clin Oncol. 2011;29: 124-126.
14. Junck L. Bevacizumab antiangiogenic therapy for glioblastoma. Neurology. 2002;76: 414-415.
15. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14: 1131-1138.
16. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28(4): 334-340.
17. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29: 142-148.
18. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated with Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme. Int J Radiat Oncol Biol Phys. 2011;17(12): 4119-4124.
19. Moen MD. Bevacizumab: in previously treated glioblastoma. Drugs. 2010;70: 181-189.
20. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27: 4733-4740.
21. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizu-mab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27: 740-745.
22. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71: 1372-1380.
23. Schiff D, Purow B. Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme. Nat Clin Pract Oncol. 2008;5: 186-187.
24. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25: 4722-4729.
25. Chowdhary S, Wong ET. Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme-improvement over available therapy? Nat Clin Pract Neurol. 2008;4: 242-243.
26. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28: 1963-1972.
27. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27: 2542-2552.
28. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122: 322-328.
29. Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009;66: 999-1013.
30. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19: 927-934.
31. van der Veldt AA, de Boer MP, Boven E, et al. Reduction in skin micro-vascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs. 2010;21: 439-446.
32. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289: 2560-2572.
33. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49: 186-193.
34. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23: 460-468.
35. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48: 9-17.
36. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9: 117-123.
37. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43: 490-501.
38. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endo-thelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102: 596-604.
39. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20: 807-815.
40. Yeh J, Frieze D, Martins R, et al. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother. 2010;44: 1010-1015.
41. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010;46: 439-448.
42. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358: 1129-1136.
43. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24: 682-685.
44. Overkleeft EN, Goldschmeding R, van Reekum F, et al. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 2010;21: 184-185.
45. McIntyre NJ, Taal MW. How to measure proteinuria? Curr Opin Nephrol Hypertens. 2008;17: 600-603.
46. Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe pro-teinuria in cancer patients. J Am Soc Nephrol. 2010;21: 1381-1389.
47. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28: 207-214.
48. Robinson ES, Matulonis UA, Ivy P, et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5: 477-483.
49. Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep. 2008;10: 86-91.
50. Cumurciuc R, Martinez-Almoyna L, Henry C, et al. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris). 2008;164: 605-607.
51. Lou E, Turner S, Sumrall A, et al. Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma. J Clin Oncol. 2011;29: e739-e742.
52. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99: 1232-1239.
53. Hapani S, Sher A, Chu D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010;79: 27-38.
54. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafe-nib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009;10: 967-974.
55. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2010;79: 1487-1495.
56. Gilbert MR, Wang M, Aldape K, et al. A randomized phase II trial of bevacizumab with either Irinotecan (CPT) or Dose-Dense Temozolomide (TMZ) in recurrent Glioblastoma (GBM). Neuro-Oncology. 2010;11: iv36-iv57.
57. Wen PY, Prados M, Schiff D, et al. Phase 2 study of XL184(BMS 907351), an inhibitor of MET, VEBFR2, and RET i patients with progressive glioblastoma. Journal of Clinical Oncology. 2010;28(suppl: abstr 2006).
58. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28: 2817-2823.
59. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13: 1253-1259.
60. Stark-Vance V. Bevacizumab and CPT-11 in the treatemnt of relapsed malignant glioma (abstract 342). Neuro-Oncology. 2005;7: 369.
61. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27: 5255-5261.
62. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16: 269-278.
63. Marras LC, Geerts WH, Perry Jr. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89: 640-646.
64. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106: 601-608.
65. Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010;28: 132-135.
66. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27: 4865-4873.
67. Desai AA, Vogelzang NJ, Rini BI, et al. A high rate of venous thrombo-embolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95: 1629-1636.
68. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of doc-etaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22: 2532-2539.
69. Groves MD, Puduvalli VK, Chang SM, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007;81: 271-277.
70. Fadul CE, Kingman LS, Meyer LP, et al. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol. 2008;90: 229-235.
71. Carrier M, Le Gal G, Tay J, et al. Rates of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide or Lenalidomide: A Systematic Review and Meta-Analysis. J Thromb Haemost. 2011;9(4): 653-663.
72. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300: 2277-2285.
73. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12: 1300-1310.
74. Gentoutech, Inc. Avastin (bevacizumab) solution for intravenous infusion: US prescribing Information. South San Francisco (CA). September 2009.
75. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thrombo-embolism in patients with cancer. N Engl J Med. 2003;349: 146-153.
76. Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10: 355-360.
77. Rieger J, Bahr O, Muller K, et al. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol. 2010;99: 49-56.
78. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91: 173-180.
79. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116: 5297-5305.
80. Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011;114(6): 1609-1616.
81. Zawacki WJ, Walker TG, DeVasher E, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bev-acizumab therapy. J Vasc Interv Radiol. 2009;20: 624-627; quiz 571.
82. Erinjeri JP, Fong AJ, Kemeny NE, et al. Timing of administration of bev-acizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2010;117: 1296-1301.
83. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10: 559-568.
84. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009;92: 149-155.
85. Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bev-acizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2010;13: 1143-1150.
86. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19: 577-582.